May 23, 2024
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
Revitalizing Cancer Therapy: UK Biotech Acquires Kyowa Kirin’s Former Drug for Epstein-Barr-Related Diseases
UK Biotech, Kyowa Kirin, cancer drug, Epstein-Barr virus, EBV-driven diseases, drug acquisition, therapy revival.
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry
RNA Startup ReNAgade Acquired by Competitor Following Mega-Round Funding
ReNAgade, RNA, startup, acquisition, competitor, mega-round funding, launch
Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions
340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.
Palisade Biotechnology’s Novel Ulcerative Colitis Treatment Shows Promising Results in Preclinical Studies
Palisade Biotechnology, ulcerative colitis, preclinical studies, nontoxic, mice, dogs, drug development, inflammatory bowel disease, treatment, prevention, symptoms
Revolutionary Oral Treatment for Retinal Disease Shows Promising Results in Phase II Trials
Retinal disease, oral treatment, Phase II trials, revolutionary, promising results, Rezolutes.
Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment
Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.
Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility
Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology